Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 235

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

Open access
Waterhouse, David M., Garon, Edward B., Chandler, Jason, McCleod, Michael, Hussein, Maen, Jotte, Robert, Horn, Leora, Daniel, Davey B., Keogh, George, Creelan, Ben, Einhorn, Lawrence H., Baker, Justin, Kasbari, Samer, Nikolinakos, Petros, Babu, Sunil, Couture, Felix, Leighl, Natasha B., Reynolds, Craig, Blumenschein, George, Gunuganti, Vijay, Li, Ang, Aanur, Nivedita, Spigel, David R. · 2020 · Journal of Clinical Oncology

Abstract

PURPOSE: Limited data exist on the optimal duration of immunotherapy, including for non–small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duration versus continuous therapy on the efficacy and safety of nivolumab. METHODS: Patients with previously treated advanced NSCLC received nivolumab monotherapy (3 mg/kg every 2 weeks). Those still receiving treatment at 1 year, including patients perceived to be deriving benefit despite radiographic progression, were randomly assigned to continue nivolumab until disease progression or unacceptable toxicity or to stop nivolumab with the option of on-study retreatment after disease progression (1-year fixed duration). RESULTS: Of 1,428 patients treated, 252 were randomly assigned to continuous (n = 127) or 1-year fixed-duration (n = 125) treatment (intent-to-treat [ITT] population). Of these, 89 and 85 patients in the continuous and 1-year fixed-duration arms, respectively, had not progressed (progression-free survival [PFS] population). With minimum post–random assignment follow-up of 13.5 months, median PFS was longer with continuous versus 1-year fixed-duration treatment (PFS population: 24.7 months v 9.4 months; hazard ratio [HR], 0.56 [95% CI, 0.37 to 0.84]). Median overall survival from random assignment was longer with continuous versus 1-year fixed-duration treatment in the PFS (not reached v 32.5 months; HR, 0.61 [95% CI, 0.37 to 0.99]) and ITT (not reached v 28.8 months; HR, 0.62 [95% CI, 0.42 to 0.92]) populations. Few new-onset treatment-related adverse events occurred. No new safety signals were identified. CONCLUSION: To our knowledge, these findings from an exploratory analysis represent the first randomized data on continuous versus fixed-duration immunotherapy in previously treated advanced NSCLC and suggest that continuing nivolumab beyond 1 year improves outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.20.00131

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 235

Metadata

Authors
Waterhouse, D. M., Garon, E. B., Chandler, J., McCleod, M., Hussein, M., Jotte, R., Horn, L., Daniel, D. B., Keogh, G., Creelan, B., Einhorn, L. H., Baker, J., Kasbari, S., Nikolinakos, P., Babu, S., Couture, F., Leighl, N. B., Reynolds, C., Blumenschein, G., Gunuganti, V., Li, A., Aanur, N., & Spigel, D. R.
Venue
Journal of Clinical Oncology
Published
2020-11-20
Volume
38
Issue
33
Pages
3863-3873
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3085379405
Cited by
235
References
6
FWCI
9.06
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153. https://app.cochat.ai/papers/10.1200/jco.20.00131
The paper
Waterhouse, D. M., Garon, E. B., Chandler, J., McCleod, M., Hussein, M., Jotte, R., Horn, L., Daniel, D. B., Keogh, G., Creelan, B., Einhorn, L. H., Baker, J., Kasbari, S., Nikolinakos, P., Babu, S., Couture, F., Leighl, N. B., Reynolds, C., Blumenschein, G., . . . Spigel, D. R. (2020). Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.00131

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.